General information about company

Scrip code*543213
NSE Symbol*ROSSARI
MSEI Symbol*NOTLISTED
ISIN*INE02A801020
Name of companyROSSARI BIOTECH LIMITED
Type of companyMain Board
Class of securityEquity
Date of start of financial year01-04-2026
Date of end of financial year31-03-2027
Date of board meeting when results were approved17-10-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange09-10-2026
Description of presentation currencyINR
Level of roundingMillions
Reporting TypeQuarterly
Reporting QuarterSecond quarter
Nature of report standalone or consolidatedStandalone
Whether results are audited or unaudited for the quarter endedUnaudited
Whether results are audited or unaudited for the Year to date for current period ended/year endedUnaudited
Segment ReportingSingle segment
Description of single segmentManufacturing of Specialty Chemicals for Textile, Home and Personal Care, Performance Chemicals and Animal Health and Nutrition industries
Start date and time of board meeting17-10-2026 17:48
End date and time of board meeting17-10-2026 18:30
Whether cash flow statement is applicable on companyYes
Type of cash flow statementCash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualificationNot applicable
Whether the company has any related party?Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure?Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/publicNA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of bank’s staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure.NA
(III) Whether the company is a ‘high value debt listed entity’ according to regulation 15 (1A)?No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company?Yes
Latest Date on which RPT policy is updated27-04-2026
Indicate Company website link for updated RPT policy of the Companywww.rossari.com/corporate-governance/
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter?No
No. of times funds raised during the quarter
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity?Yes



Financial Results – Ind-AS

Particulars3 months/ 6 months ended (dd-mm-yyyy)Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period01-07-202601-04-2026
Date of end of reporting period30-09-202630-09-2026
Whether results are audited or unauditedUnauditedUnaudited
Nature of report standalone or consolidatedStandaloneStandalone
Part IBlue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.
1Income
Revenue from operations4952.769775.51
Other income16.8638.74
Total income4969.629814.25
2Expenses
(a)Cost of materials consumed3145.356089.29
(b)Purchases of stock-in-trade784.961540.47
(c)Changes in inventories of finished goods, work-in-progress and stock-in-trade-214.25-351.69
(d)Employee benefit expense 208.82412.69
(e)Finance costs20.7759.2
(f)Depreciation, depletion and amortisation expense107.33190.69
(g)Other Expenses
1Other Expenses455.11947.86
Total other expenses455.11947.86
Total expenses4508.098888.51
3Total profit before exceptional items and tax461.53925.74
4Exceptional items 00
5Total profit before tax461.53925.74
6Tax expense
7Current tax120.28240.16
8Deferred tax-1.060.61
9Total tax expenses119.22240.77
10Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement00
11Net Profit Loss for the period from continuing operations342.31684.97
12Profit (loss) from discontinued operations before tax00
13Tax expense of discontinued operations00
14Net profit (loss) from discontinued operation after tax00
15Share of profit (loss) of associates and joint ventures accounted for using equity method00
16Total profit (loss) for period342.31684.97
17Other comprehensive income net of taxes-0.13-0.25
18Total Comprehensive Income for the period342.18684.72
19Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21Details of equity share capital
Paid-up equity share capital110.79110.79
Face value of equity share capital22
22Reserves excluding revaluation reserve
23Earnings per share
iEarnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations6.1812.37
Diluted earnings (loss) per share from continuing operations6.1812.36
iiEarnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations00
Diluted earnings (loss) per share from discontinued operations00
iiiEarnings per equity share (for continuing and discontinued operations)
Basic earnings (loss) per share from continuing and discontinued operations6.1812.37
Diluted earnings (loss) per share from continuing and discontinued operations6.1812.36
24Debt equity ratioTextual Information( 1)
25Debt service coverage ratioTextual Information( 2)
26Interest service coverage ratioTextual Information( 3)
27Disclosure of notes on financial resultsTextual Information(4)

Text Block

Textual Information(4)1. The value of the related party transaction approved by the audit committee represents the value approved by audit committee of the respective company, as applicable. 2. Remuneration does not include stock options granted in accordance with the Rossari Employee Stock Option Plan- 2019, these options would vest after fulfilment of vesting conditions in accordance with the plan. Remuneration reported pertains to the amount paid during the period. 3. Transactions between members of the Group (between Rossari Biotech Limited and its subsidiary or between subsidiaries) are reported once. 4. The related transactions have been valued at the Average rate for the half year ended 30th September Further all the closing balances are valued at Closing rate as on 30th September 2026. (wherever necessary). 5.. For transactions between foreign subsidiaries, the conversion rate as on September 30, 2026 was applied.



Statement of Asset and Liabilities

ParticularsHalf Year ended (dd-mm-yyyy)
Date of start of reporting period01-04-2026
Date of end of reporting period30-09-2026
Whether results are audited or unauditedUnaudited
Nature of report standalone or consolidatedStandalone
Assets
1 Non-current assets
Property, plant and equipment2095.2
Capital work-in-progress786.72
Investment property
Goodwill10.6
Other intangible assets442.43
Intangible assets under development
Biological assets other than bearer plants
Investments accounted for using equity method
Non-current financial assets
Non-current investments5125.08
Trade receivables, non-current
Loans, non-current0
Other non-current financial assets
1Other Financial Assets34.33
2
3
4
5
Details of other non-current financial assets
Total of other non-current financial assets34.33
Total non-current financial assets5159.41
Deferred tax assets (net)32.62
Other non-current assets
1Income Tax Assets (Net)52.62
2Other non-current assets107.18
3
4
5
Details of other non-current assets
Total of other non-current assets159.8
Total non-current assets8686.78
2Current assets
Inventories2037.87
Current financial asset
Current investments300.22
Trade receivables, current5243.63
Cash and cash equivalents669.83
Bank balance other than cash and cash equivalents38.98
Loans, current409.8
Other current financial assets
1Other financial assets265.46
2
3
4
5
Details of other current financial assets
Total of Other current financial assets265.46
Total current financial assets6927.92
Current tax assets (net)
Other current assets
1Other current assets341.1
2
3
4
5
Details of other current assets
Total of other current assets341.1
Total current assets9306.89
3Non-current assets classified as held for sale
4Regulatory deferral account debit balances and related deferred tax Assets
Total assets17993.67
Equity and liabilities
1Equity
Equity attributable to owners of parent
Equity share capital110.79
Other equity12750.77
Total equity attributable to owners of parent12861.56
Non controlling interest
Total equity12861.56
2Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current46.11
Trade Payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises
Total Trade payable
Other non-current financial liabilities
1Lease Liabilities112.87
2
3
4
5
Details of other non-current financial liabilities
Total of other non-current financial liabilities112.87
Total non-current financial liabilities158.98
Provisions, non-current59.23
Deferred tax liabilities (net)
Deferred government grants, Non-current
Other non-current liabilities
1
2
3
4
5
Details of other non-current liabilities
Total of other non-current liabilities
Total non-current liabilities218.21
Current liabilities
Current financial liabilities
Borrowings, current805.37
Trade Payables, current
(A) Total outstanding dues of micro enterprises and small enterprises231.52
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises3426.09
Total Trade payable3657.61
Other current financial liabilities
1Lease Liabilities44.5
2Other financial liabilities191.65
3
4
5
Details of other current financial liabilities
Total of other current financial liabilities236.15
Total current financial liabilities4699.13
Other current liabilities
1Other current liabilities88.08
2
3
4
5
Details of other current liabilities
Total of other current liabilities88.08
Provisions, current40.02
Current tax liabilities (Net)86.67
Deferred government grants, Current
Total current liabilities4913.9
3Liabilities directly associated with assets in disposal group classified as held for sale
4Regulatory deferral account credit balances and related deferred tax liability
Total liabilities5132.11
Total equity and liabilities17993.67
Disclosure of notes on assets and liabilities

Other Comprehensive Income

Date of start of reporting period01-07-202601-04-2026
Date of end of reporting period30-09-202630-09-2026
Whether results are audited or unauditedUnauditedUnaudited
Nature of report standalone or consolidatedStandaloneStandalone
Other comprehensive income [Abstract]
1Amount of items that will not be reclassified to profit and loss
1Remeasurements of the defined benefit plans-0.17-0.33
Total Amount of items that will not be reclassified to profit and loss-0.17-0.33
2Income tax relating to items that will not be reclassified to profit or loss -0.04-0.08
3Amount of items that will be reclassified to profit and loss
Total Amount of items that will be reclassified to profit and loss
4Income tax relating to items that will be reclassified to profit or loss
5Total Other comprehensive income-0.13-0.25


Cash flow statement, indirect

ParticularsHalf Year ended (dd-mm-yyyy)
Date of start of reporting period01-04-2026
Date of end of reporting period30-09-2026
Whether results are audited or unauditedUnaudited
Nature of report standalone or consolidatedStandalone
Part IBlue color marked fields are non-mandatory.
1Statement of cash flows
Cash flows from used in operating activities
Profit before tax925.74
2Adjustments for reconcile profit (loss)
Adjustments for finance costs63.24
Adjustments for decrease (increase) in inventories-240.6
Adjustments for decrease (increase) in trade receivables, current71.44
Adjustments for decrease (increase) in trade receivables, non-current0
Adjustments for decrease (increase) in other current assets0
Adjustments for decrease (increase) in other non-current assets0
Adjustments for other financial assets, non-current0
Adjustments for other financial assets, current0
Adjustments for other bank balances0
Adjustments for increase (decrease) in trade payables, current57.08
Adjustments for increase (decrease) in trade payables, non-current0
Adjustments for increase (decrease) in other current liabilities0
Adjustments for increase (decrease) in other non-current liabilities0
Adjustments for depreciation and amortisation expense190.69
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss0
Adjustments for provisions, current23.5
Adjustments for provisions, non-current0
Adjustments for other financial liabilities, current-0.09
Adjustments for other financial liabilities, non-current0
Adjustments for unrealised foreign exchange losses gains22.66
Adjustments for dividend income0
Adjustments for interest income18.61
Adjustments for share-based payments8.59
Adjustments for fair value losses (gains)-4.73
Adjustments for undistributed profits of associates0
Other adjustments for which cash effects are investing or financing cash flow-7.53
Other adjustments to reconcile profit (loss)0
Other adjustments for non-cash items0.49
Share of profit and loss from partnership firm or association of persons or limited liability partnerships0
Total adjustments for reconcile profit (loss)166.13
Net cash flows from (used in) operations1091.87
Dividends received0
Interest paid0
Interest received0
Income taxes paid (refund)215.25
Other inflows (outflows) of cash0
Net cash flows from (used in) operating activities876.62
3Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses0
Cash flows used in obtaining control of subsidiaries or other businesses0
Other cash receipts from sales of equity or debt instruments of other entities54.28
Other cash payments to acquire equity or debt instruments of other entities0
Other cash receipts from sales of interests in joint ventures0
Other cash payments to acquire interests in joint ventures0
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships0
Cash payment for investment in partnership firm or association of persons or limited liability partnerships0
Proceeds from sales of property, plant and equipment2.88
Purchase of property, plant and equipment238.23
Proceeds from sales of investment property0
Purchase of investment property0
Proceeds from sales of intangible assets0
Purchase of intangible assets0
Proceeds from sales of intangible assets under development0
Purchase of intangible assets under development0
Proceeds from sales of goodwill0
Purchase of goodwill0
Proceeds from biological assets other than bearer plants0
Purchase of biological assets other than bearer plants0
Proceeds from government grants0
Proceeds from sales of other long-term assets0
Purchase of other long-term assets0
Cash advances and loans made to other parties0
Cash receipts from repayment of advances and loans made to other parties0
Cash payments for future contracts, forward contracts, option contracts and swap contracts0
Cash receipts from future contracts, forward contracts, option contracts and swap contracts0
Dividends received0
Interest received14.01
Income taxes paid (refund)0
Other inflows (outflows) of cash-0.75
Net cash flows from (used in) investing activities-167.81
4Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries0
Payments from changes in ownership interests in subsidiaries0
Proceeds from issuing shares4.57
Proceeds from issuing other equity instruments0
Payments to acquire or redeem entity's shares0
Payments of other equity instruments0
Proceeds from exercise of stock options0
Proceeds from issuing debentures notes bonds etc0
Proceeds from borrowings0
Repayments of borrowings413.62
Payments of lease liabilities26.57
Dividends paid27.7
Interest paid59.65
Income taxes paid (refund)0
Other inflows (outflows) of cash0
Net cash flows from (used in) financing activities-522.97
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes185.84
5Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents-2.49
Net increase (decrease) in cash and cash equivalents183.35
Cash and cash equivalents cash flow statement at beginning of period486.48
Cash and cash equivalents cash flow statement at end of period669.83



Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)

Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.
Sr. No.Details of the party (listed entity /subsidiary) entering into the transactionDetails of the counterpartyType of related party transactionDetails of other related party transactionValue of the related party transaction as approved by the audit committeeRemarks on approval by audit committeeValue of the related party transaction ratified by the audit committeeDate of Audit Committee Meeting where the ratification was approvedValue of transaction during the reporting periodIn case monies are due to either party as a result of the transactionIn case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investmentsDetails of the loans, inter-corporate deposits, advances or investments
NamePANNamePANRelationship of the counterparty with the listed entity or its subsidiaryOpening balanceClosing balanceNature of indebtedness (loan/ issuance of debt/ any other etc.)Details of other indebtednessCostTenureNature (loan/ advance/ intercorporate deposit/ investment)Interest Rate (%)TenureSecured/ unsecuredPurpose for which the funds will be utilised by the ultimate recipient of funds (endusage)Notes
1Rossari Biotech LimitedSunil ChariKey Managerial PersonnelRemunerationAs per the Companies Act, 2013 and Shareholders' Approval 2.8400
2Rossari Biotech LimitedEdward MenezesKey Managerial PersonnelRemunerationAs per the Companies Act, 2013 and Shareholders' Approval 2.8400
3Rossari Biotech LimitedMikhail MenezesRelative of DirectorRemunerationAs per the Companies Act, 2013 and Shareholders' Approval 5.3700
4Rossari Biotech LimitedYash ChariRelative of DirectorRemunerationAs per the Companies Act, 2013 and Shareholders' Approval 0.5800
5Rossari Biotech LimitedKetan SablokKey Managerial PersonnelRemunerationAs per the Companies Act, 2013 and Shareholders' Approval 14.6900
6Rossari Biotech LimitedParul GuptaKey Managerial PersonnelRemunerationAs per the Companies Act, 2013 and Shareholders' Approval 2.2500
7Rossari Biotech LimitedRupesh RupareliaKey Managerial PersonnelRemunerationAs per the Companies Act, 2013 and Shareholders' Approval 3.0300
8Rossari Biotech LimitedAseem DhruIndependent DirectorAny other transactionSitting FeesNA0.500
9Rossari Biotech LimitedGurudas ArasIndependent DirectorAny other transactionSitting FeesNA0.900
10Rossari Biotech LimitedAparna SharmaIndependent DirectorAny other transactionSitting FeesNA0.400
11Rossari Biotech LimitedEsha AchanIndependent DirectorAny other transactionSitting FeesNA0.900
12Rossari Biotech LimitedUdeypaul Singh GillIndependent DirectorAny other transactionSitting FeesNA0.400
13Rossari Biotech LimitedBuzil Rossari Private LimitedWholly Owned Subsidiary CompanySale of goods or services750NA217.32802.291012.65
14Rossari Biotech LimitedBuzil Rossari Private LimitedWholly Owned Subsidiary CompanyPurchase of goods or services30NA0.990.2311.34
15Rossari Biotech LimitedBuzil Rossari Private LimitedWholly Owned Subsidiary CompanyLoan500NA0240240Loan8.00%On DemandUnsecuredGeneral Business Requirement
16Rossari Biotech LimitedBuzil Rossari Private LimitedWholly Owned Subsidiary CompanyInterest received500NA9.6800
17Rossari Biotech LimitedBuzil Rossari Private LimitedWholly Owned Subsidiary CompanyAny other transactionEmployee Cost - Recovery100NA7.9900
18Rossari Biotech LimitedBuzil Rossari Private LimitedWholly Owned Subsidiary CompanyAny other transactionEmployee Cost - Reimbursement100NA10.0500
19Rossari Biotech LimitedBuzil Rossari Private LimitedWholly Owned Subsidiary CompanyAny other transactionRecovery of Expenses100NA4.3900
20Rossari Biotech LimitedRossari Consumer Products Private LimitedWholly Owned Subsidiary CompanySale of goods or services600NA101.64316.09375.92
21Rossari Biotech LimitedRossari Consumer Products Private LimitedWholly Owned Subsidiary CompanyAny other transactionEmployee Cost - Recovery50NA1.0100
22Rossari Biotech LimitedRossari Consumer Products Private LimitedWholly Owned Subsidiary CompanyAny other transactionRecovery of Expenses50NA0.8600
23Rossari Biotech LimitedTristar Intermediates Private LimitedWholly Owned Subsidiary CompanySale of goods or services150NA27.64101.2925.97
24Rossari Biotech LimitedTristar Intermediates Private LimitedWholly Owned Subsidiary CompanyAny other transactionCommission IncomeNA10.0300
25Rossari Biotech LimitedTristar Intermediates Private LimitedWholly Owned Subsidiary CompanyPurchase of goods or services2500NA1264.211040.85733.59
26Rossari Biotech LimitedTristar Intermediates Private LimitedWholly Owned Subsidiary CompanyPurchase of fixed assets25NA1.1400
27Rossari Biotech LimitedTristar Intermediates Private LimitedWholly Owned Subsidiary CompanyAny other transactionEmployee Cost - Recovery100NA26.7700
28Rossari Biotech LimitedTristar Intermediates Private LimitedWholly Owned Subsidiary CompanyAny other transactionRecovery of Expenses100NA1.3400
29Rossari Biotech LimitedUnitop Chemicals Private LimitedSubsidiary CompanySale of goods or services2880NA380.75467.29377.34
30Rossari Biotech LimitedUnitop Chemicals Private LimitedSubsidiary CompanyAny other transactionCommission Income2880NA81.2200
31Rossari Biotech LimitedUnitop Chemicals Private LimitedSubsidiary CompanySale of fixed assets50NA0.8300
32Rossari Biotech LimitedUnitop Chemicals Private LimitedSubsidiary CompanyPurchase of goods or services7000NA2434.291308.751312.31
33Rossari Biotech LimitedUnitop Chemicals Private LimitedSubsidiary CompanyPurchase of fixed assets50NA2.0500
34Rossari Biotech LimitedUnitop Chemicals Private LimitedSubsidiary CompanyAny other transactionEmployee Cost - Recovery300NA66.8200
35Rossari Biotech LimitedUnitop Chemicals Private LimitedSubsidiary CompanyAny other transactionRecovery of Expenses300NA11.6800
36Rossari Biotech LimitedRomakk Chemicals Private LimitedAssociateSale of goods or services60NA0.872.082.31
37Rossari Biotech LimitedRomakk Chemicals Private LimitedAssociatePurchase of goods or services400NA136.9590.19131.39
38Rossari Biotech LimitedRomakk Chemicals Private LimitedAssociateAny other transactionEmployee Cost - Recovery20NA2.6700
39Rossari Biotech LimitedRomakk Chemicals Private LimitedAssociateAny other transactionRecovery of ExpensesNA0.3300
40Rossari Biotech LimitedK. K. Chempro (India) Private LimitedRelated Party to Romakk Chemicals Private Limited (subsidiary company)Any other transactionReceivables AcNA00.010.01
41Rossari Biotech LimitedINSAI CHEMPLAST (Formerly known as K K CHEMICAL INDUSTRIES)Related Party to Romakk Chemicals Private Limited (subsidiary company)Any other transactionPayable Ac (Dr.Bal)NA00.050.05
42Rossari Biotech LimitedMcCoy Performance Silicones Private LimitedRelated Party to Romakk Chemicals Private Limited (subsidiary company)Any other transactionPayable Ac (Dr.Bal)NA00.010.01
43Rossari Biotech LimitedRossari Global FZCO (Formerly known as Rossari Global DMCC)Wholly Owned Subsidiary CompanyLoan360NA0117.59120.04Loan10.00%On DemandUnsecuredGeneral Business Requirement
44Rossari Biotech LimitedRossari Global FZCO (Formerly known as Rossari Global DMCC)Wholly Owned Subsidiary CompanyInterest received36NA5.9915.7917.99
45Rossari Biotech LimitedRossari Global FZCO (Formerly known as Rossari Global DMCC)Wholly Owned Subsidiary CompanyAny other transactionRecovery of Expenses10NA0.252.343.33
46Rossari Biotech LimitedRossari Global FZCO (Formerly known as Rossari Global DMCC)Wholly Owned Subsidiary CompanyAny other transactionCorporate Guarantee Given168NA0149.08151.17
47Rossari Biotech LimitedRossari Global FZCO (Formerly known as Rossari Global DMCC)Wholly Owned Subsidiary CompanyAny other transactionCorporate Guarantee Commission Income1.7NA0.7500
48Rossari Biotech LimitedRossari Biotech Trading FZEStep Down Wholly Owned SubsidiarySale of goods or services4000NA1496.43378.68913.07
49Rossari Biotech LimitedRossari Biotech Trading FZEStep Down Wholly Owned SubsidiaryAny other transactionRecovery of Expenses5NA0.9400
50Rossari Biotech LimitedRossari Biotech Trading FZEStep Down Wholly Owned SubsidiaryAny other transactionCorporate Guarantee Given672NA0596.32604.67
51Rossari Biotech LimitedRossari Biotech Trading FZEStep Down Wholly Owned SubsidiaryAny other transactionCorporate Guarantee Commission Income67NA3.0100
52Rossari Biotech LimitedUnistar Thai Company LimitedStep Down Wholly Owned SubsidiarySale of goods or services1080NA8.929.1723.13
53Rossari Biotech LimitedUnistar Thai Company LimitedStep Down Wholly Owned SubsidiaryPurchase of goods or services550NA2.7200
54Rossari Biotech LimitedUnistar Thai Company LimitedStep Down Wholly Owned SubsidiaryAny other transactionRecovery of Expenses10NA0.0700
55Rossari Biotech LimitedUnistar Thai Company LimitedStep Down Wholly Owned SubsidiaryAny other transactionCorporate Guarantee Given840NA0745.4755.84
56Rossari Biotech LimitedUnistar Thai Company LimitedStep Down Wholly Owned SubsidiaryAny other transactionCorporate Guarantee Commission Income8.4NA3.7600
57Rossari Biotech LimitedK K Chem India Private LimitedRelated Party to Romakk Chemicals Private Limited (subsidiary company)Purchase of goods or services50NA2.140.490.43
58Rossari Biotech LimitedRossari International Limited CompanyWholly Owned Subsidiary CompanyLoan1000NA025.0325.57Loan7.22%On DemandUnsecuredGeneral Business Requirement
59Rossari Biotech LimitedRossari International Limited CompanyWholly Owned Subsidiary CompanyInterest received100NA0.890.771.71
60Rossari Biotech LimitedRossari International Limited CompanyWholly Owned Subsidiary CompanyAny other transactionRecovery of Expenses100NA7.827.7715.59
61Unitop Chemicals Private LimitedGurudas ArasIndependent DirectorAny other transactionSitting FeesNA0.1500
62Unitop Chemicals Private LimitedAparna SharmaIndependent DirectorAny other transactionSitting FeesNA0.1300
63Unitop Chemicals Private LimitedTristar Intermediates Private LimitedFellow SubsidiarySale of goods or services500NA343.27251.01321.31
64Unitop Chemicals Private LimitedTristar Intermediates Private LimitedFellow SubsidiaryPurchase of goods or services500NA287.8575.436.97
65Unitop Chemicals Private LimitedBuzil Rossari Private LimitedFellow SubsidiaryPurchase of goods or services10NA00.551.2
66Unitop Chemicals Private LimitedBuzil Rossari Private LimitedFellow SubsidiaryAny other transactionPurchase of fixed assets10NA0.2500
67Unitop Chemicals Private LimitedBuzil Rossari Private LimitedFellow SubsidiaryAny other transactionReimbursement5NA2.0100
68Unitop Chemicals Private LimitedHextar Unitop SDN.BHD.Joint VentureSale of goods or services60NA25.792.997.25
69Unitop Chemicals Private LimitedRomakk Chemicals Private LimitedAssociate of Holding CompanySale of goods or services12.5NA1.2400
70Unitop Chemicals Private LimitedRomakk Chemicals Private LimitedAssociate of Holding CompanyPurchase of goods or services150NA9.22010.87
71Unitop Chemicals Private LimitedGlad Properties (India) Private LimitedPromoter Group CompanyAny other transactionRent2.4NA1.020.220
72Tristar Intermediates Private LimitedGurudas ArasIndependent DirectorAny other transactionSitting FeesNA0.0500
73Tristar Intermediates Private LimitedBuzil Rossari Private LimitedFellow SubsidiaryPurchase of goods or services10NA00.190.38
74Tristar Intermediates Private LimitedBuzil Rossari Private LimitedFellow SubsidiaryAny other transactionReimbursement Expenses (Employee)5NA0.6300
75Tristar Intermediates Private LimitedRomakk Chemicals Private LimitedFellow SubsidiarySale of goods or services12.5NA00.010
76Buzil Rossari Private LimitedRockdude Impex Private LimitedRelated Party of Fellow SubsidiarySale of goods or services1000NA119.9158.5556.04
77Buzil Rossari Private LimitedRockdude Impex Private LimitedRelated Party of Fellow SubsidiaryPurchase of goods or services1000NA148.82-466.43-223.02
78Romakk Chemicals Private LimitedNitin SethiKey Managerial PersonnelRemuneration5NA2.500
79Romakk Chemicals Private LimitedAmit MalhotraKey Managerial PersonnelRemuneration2.4NA1.200
80Romakk Chemicals Private LimitedGurudas ArasIndependent DirectorAny other transactionSitting FeesNA0.1300
81Romakk Chemicals Private LimitedEsha AchanIndependent DirectorAny other transactionSitting FeesNA0.1300
82Romakk Chemicals Private LimitedK K Chem India Private LimitedEnterprises on which Director or their relatives are able to exercise significant influenceSale of goods or services1NA00.40
83Romakk Chemicals Private LimitedK K Chem India Private LimitedEnterprises on which Director or their relatives are able to exercise significant influencePurchase of goods or services50NA14.152.828.73
84Romakk Chemicals Private LimitedNitin Sethi (HUF)Enterprises on which Director or their relatives are able to exercise significant influenceAny other transactionRent2.1NA1.050.070.16
85Romakk Chemicals Private LimitedSumant Agrawal (HUF)Enterprises on which Director or their relatives are able to exercise significant influenceAny other transactionRent2.1NA1.050.080.19
86Rossari Global FZCO (Formerly known as Rossari Global DMCC)Sunil ChariDirectorRemunerationAs per the Companies Act, 20134.8800
87Rossari Global FZCO (Formerly known as Rossari Global DMCC)Yashika ChariRelative of DirectorRemunerationAs per the Companies Act, 20134.4600
88Rossari Global FZCO (Formerly known as Rossari Global DMCC)Rupesh RupareliaManagerRemunerationAs per SEBI LODR,20150.9300
89Rossari Global FZCO (Formerly known as Rossari Global DMCC)Rossari Biotech Trading FZEWholly Owned Subsidiary CompanyLoan95.98NA10.3625.5615.66Loan10.00%On DemandUnsecuredGeneral Business Requirement
90Rossari Global FZCO (Formerly known as Rossari Global DMCC)Rossari Biotech Trading FZEWholly Owned Subsidiary CompanyInterest received9.6NA1.010.730.26
91Rossari Global FZCO (Formerly known as Rossari Global DMCC)Unistar Thai Company LimitedWholly Owned Subsidiary CompanyLoan86.38NA028.1228.7
92Rossari Global FZCO (Formerly known as Rossari Global DMCC)Unistar Thai Company LimitedWholly Owned Subsidiary CompanyInterest received8.6NA1.430.750.48
93Rossari International Limited CompanyRupesh RupareliaManagerRemunerationAs per SEBI LODR,20150.7600
94Rossari Biotech Trading FZEEdward MenezesDirectorRemunerationAs per the Companies Act, 20136.1900
95Rossari Biotech Trading FZEYash ChariDirectorRemunerationAs per the Companies Act, 20134.700
96Rossari Biotech LimitedPrasad GadkariDirector of SubsidiaryRemunerationAs per the Companies Act, 2013 and SEBI LODR,20156.9200
97Rossari Biotech LimitedPravin DeokarDirector of SubsidiaryRemunerationAs per the Companies Act, 2013 and SEBI LODR,20151.3900
98Tristar Intermediates Private LimitedSanjay MarballiDirectorRemunerationAs per the Companies Act, 2013 and SEBI LODR,20156.7600
99Tristar Intermediates Private LimitedKrishna Kumar TiwariDirectorRemunerationAs per the Companies Act, 2013 and SEBI LODR,20151.2500
Total value of transaction during the reporting period7383.48



Format for Disclosing Outstanding Default on Loans and Debt Securities

Sr. No.ParticularsAmountRemarks
1.Loans / revolving facilities like cash credit from banks / financial institutions
ATotal amount outstanding as on date0
BOf the total amount outstanding, amount of default as on date0
2.Unlisted debt securities i.e. NCDs and NCRPS
ATotal amount outstanding as on date0
BOf the total amount outstanding, amount of default as on date0
3.Total financial indebtedness of the listed entity including short-term and long-term debt0